exoASO STAT6
Alternative Names: CDK 004; exoASO™-STAT6Latest Information Update: 28 Jul 2024
At a glance
- Originator Codiak BioSciences
- Class Antineoplastics; Antisense oligonucleotides; Exosome therapies; Immunotherapies
- Mechanism of Action RNA interference; STAT6 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Liver cancer; Liver metastases
- No development reported Colorectal cancer; Glioma; Lung cancer; Ovarian cancer; Pancreatic cancer; Thyroid cancer; Uveal melanoma
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (IV)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Glioma in USA (IV)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Lung-cancer in USA (IV)